Agenda Day 3

9:00 AM - 9:45 AM IP Monetisation in the Life Sciences: A Broader Perspective

, ,
This session explores a variety of ways to monetise
your company’s IP without litigation, focusing on
licensing patents to start-ups, right of reference to
clinical data, software and tools, and technology
licenses outside of your core markets. Taking a
broad view of unused and non-core IP including
trademarks and discontinued products opens up
additional opportunities to monetise a life-science
IP portfolio.

9:45 AM - 10:30 AM A Smart Monetisation Strategy

, ,
An assessment of the various options available to
your organisation with regards to monetisation,
from asserting patents, cross-licensing, and using
licenses as a bargaining chip for collaboration.

11:00 AM - 11:45 AM Secondary patents for further medical uses: Is it worth investing?

, ,
In a multi-jurisdictional context, secure patent
protection for further medical use arising from a
new clinical development is challenging, depending
on the background of the product and on the
legal framework. Are those “second medical use”
claims enforceable, and are injunctions easily
granted? What are the remedies to be expected?
Distortion coming from regulatory authorities and
legal framework may be an additional barrier for a
valuable protection of those further medical uses

1:20 PM - 2:05 PM Interactive Discussion Group: What is Eligible for Protection?

, , , , , ,
With uncertainty in the EU over what kind of
life science subject-matter is eligible for patent
protection, what knowledge can be gained from
case law and wider competitive awareness of
what colleagues are doing which is considered
‘safe’ so that you might find stability in your own
department’s work? This session will include
information around exceptions within patentability
as well as detail on when to file.

2:05 PM - 2:50 PM The Interplay Between IP Laws and Biodiversity Legislation: Why You Should be Paying Attention

Why should you and your department care
about this link between the legislation? How do
the two fit together in reality? And, are we seeing
‘IP on Life’ entering through the backdoor? Attend
this session to find out the answers to these
questions, as well as to challenge our panellists by
posing your own questions around the subject.

3:35 PM - 4:20 PM Complications With SPCs

, ,
SPCs are becoming an increasingly important
means of extending the life of IP protection
for biopharma and pharma drug products. This
session will assess the new versus the old- delving
into what the new system will look at and how it
compares- as well as recent CJEU referrals.

4:20 PM - 5:05 PM When Competition and IP Law Collide

, ,
Competition authorities around the world are
targeting pharmaceutical companies in a
string of cases where the patent-holders right
to maximise profits from its patented product
are being called into question. When IP and
competition law meet, as an IP lawyer, what is
your responsibility? What, if any, changes are
needed to your approach to reflect the heightened
competition law risks in the current climate?